Volume | 96,876 |
|
|||||
News | - | ||||||
Day High | 34.625 | Low High |
|||||
Day Low | 32.27 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | CRBP | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
33.33 | 32.27 | 34.625 | 34.25 | 33.50 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,148 | 96,876 | $ 33.73 | $ 3,267,197 | - | 3.0334 - 49.8699 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
18:34:14 | 1 | $ 34.97 | USD |
Corbus Pharmaceuticals Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
359.49M | 10.49M | - | 0 | -44.6M | -4.25 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Corbus Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CRBP Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 35.79 | 40.08 | 32.0288 | 37.21 | 248,018 | -1.54 | -4.30% |
1 Month | 39.24 | 45.00 | 32.0288 | 38.71 | 236,035 | -4.99 | -12.72% |
3 Months | 26.36 | 49.8699 | 20.21 | 35.61 | 298,871 | 7.89 | 29.93% |
6 Months | 5.72 | 49.8699 | 3.0334 | 29.60 | 505,047 | 28.53 | 498.78% |
1 Year | 9.01 | 49.8699 | 3.0334 | 28.78 | 262,600 | 25.24 | 280.13% |
3 Years | 52.50 | 68.70 | 2.11 | 19.93 | 1,305,882 | -18.25 | -34.76% |
5 Years | 215.10 | 322.50 | 2.11 | 64.86 | 2,195,639 | -180.85 | -84.08% |
Corbus Pharmaceuticals Description
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune system. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. |